Novartis antitrust lawyer sceptical of innovation review in pharma mergers
The head of Novartis’ antitrust legal team yesterday said innovation considerations while reviewing mergers in the pharmaceutical industry may be a solution in search of a problem.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access